At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 77 enrolled
Drug / intervention
MEDI1814 for IV injection +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.
In Brief
A Phase 1 clinical trial evaluating MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, and 2 other interventions for Mild-Moderate Alzheimer's Disease and Healthy Elderly. Completed, enrolled 77 participants across 10 sites.
Detailed Summary
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild-Moderate Alzheimer's Disease, Healthy Elderly
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartFeb 2014
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 15, 2014
Enrollment StartFeb 4, 2014
Primary CompletionSep 15, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.5 years ago
Interventions
MEDI1814 for IV injectionbiological
Monoclonal antibody for IV Injection
MEDI1814 for Subcutaneous Injectionbiological
Monoclonal antibody for subcutaneous injection
IV Placebobiological
Placebo for IV injection
Placebo for Subcutaneous Injectionbiological
Subcutaneous Placebo Injection